Amarin (AMRN) -6.8% after saying that doesn't expect a decision from the FDA this month on whether to grant the company's request for five-year marketing exclusivity for its Vascepa heart pill, which the agency approved in July. Amarin doesn't haven't a clue whether the FDA will grant its request or when it will make a decision. [View news story]
I'm an investor in AMRN and am convinced that if the FDA is continuing to consider NCE status instead of just saying no, that they are extremely close to yes rather than no. They don't delay an outcome this long if they aren't very close to an approval.
Amarin's Performance Issues: Here To Stay? [View article]
Amarin (AMRN) -6.8% after saying that doesn't expect a decision from the FDA this month on whether to grant the company's request for five-year marketing exclusivity for its Vascepa heart pill, which the agency approved in July. Amarin doesn't haven't a clue whether the FDA will grant its request or when it will make a decision. [View news story]